TipRanks on MSN

Cogent Biosciences’ Phase 2 Study on Bezuclastinib: A Potential Game-Changer for Advanced Systemic Mastocytosis

Cogent Biosciences, Inc. (($COGT)) announced an update on their ongoing clinical study. Cogent Biosciences, Inc. is conducting a Phase 2 clinical ...

Sanofi: Is Dupixent Too Successful?

Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.

Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...
Frontiers

Mast cell activation disorders: Mechanisms, diagnostics, and translational approaches

Mast cell activation disorders (MCAD) encompass a wide range of immune-mediated conditions characterized by episodic or chronic mast cell activation, ...

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...